Mendel.ai is a technology company.
Mendel.ai has raised $63.0M across 4 funding rounds.
Mendel.ai has raised $63.0M in total across 4 funding rounds.
Mendel.ai has raised $63.0M in total across 4 funding rounds.
Mendel.ai's investors include Access Industries, AirAngels, Beringea, Bling Capital, Curious Capital, DCM, Insight Partners, Matrix, NewView Capital, Oak HC/FT, Precursor Ventures, Scale Venture Partners.
Mendel.ai is a San Jose-based healthcare AI company founded in 2017 that builds software to extract, structure, and analyze complex clinical data from structured and unstructured sources like electronic medical records (EMRs).[1][2][3][4] It serves life sciences organizations, healthcare providers, and clinical research teams by solving inefficiencies in data workflows—such as manual cohort identification, patient matching, and trial prescreening—through scalable, explainable AI that eliminates hallucinations and delivers clinician-like reasoning.[1][3][5][6] Key products include the Hypercube chat interface for natural language queries, AI co-pilots for tasks like abstraction and prior authorization, and tools for optical character recognition (OCR), de-identification, and cohort retrieval, powering faster drug development, research, and patient care with 100% explainability.[3][4][5]
The company has shown strong growth momentum, backed by investors like Oak HC/FT and DCM, with a team exceeding 100 members and clients among leading life sciences firms; recent benchmarks demonstrate it outperforming GPT-4 in automatic cohort retrieval, and studies (e.g., with University of Pennsylvania) confirm human-AI teams achieve faster, equally accurate oncology trial prescreening.[3][4][6]
Mendel.ai was co-founded in 2017 by Karim Galil, a trained physician and CEO/Chairman, and Wael Salloum, an AI scientist and Chief Science Officer, in a two-person Silicon Valley office, blending medical expertise with computer science to address gaps in clinical data handling.[1][4][5] Galil's vision stemmed from practicing medicine, where he sought AI that could reason clinically with full explainability and no hallucinations, while Salloum brought AI rigor; after five years and millions in R&D, they launched their first model.[4][5]
Key leadership includes CTO Sudhir Srinivas and CFO Hubert Lin, with backing from investors like Oak HC/FT and DCM.[1] Early traction built through proprietary tech development, evolving into a platform trusted by top life sciences clients, marked by pivotal advancements like the neuro-symbolic AI system outperforming GPT-4 and real-world validations in oncology prescreening.[3][6]
Mendel.ai rides the generative AI wave in healthcare, targeting the explosion of unstructured clinical data (e.g., EMRs with hundreds of pages per oncology patient) amid talent shortages and rising demand for precision medicine, clinical trials, and data-driven care.[3][5][6] Timing aligns with post-2023 LLM advancements and regulatory pushes for explainable AI, amplified by market forces like pharma's need for faster trials and providers' workflow strains—unlocking value from siloed data warehouses.[2][4][5]
It influences the ecosystem by setting standards for trustworthy clinical AI, partnering with AWS and Google Cloud for scalable infrastructure, and validating human-AI collaboration (e.g., ASCO 2024 study), potentially accelerating drug development and reducing costs industry-wide.[4][5][6]
Mendel.ai is poised to dominate clinical AI with its hallucination-proof, explainable tech, expanding Hypercube and co-pilots to more workflows like real-time decision support and personalized medicine.[3][4][5] Trends like multimodal AI integration, stricter FDA guidelines on explainability, and healthcare's data deluge will propel growth, especially as blue-chip clients scale adoption. Its influence may evolve from disruptor to infrastructure layer, supercharging life sciences efficiency and tying back to its origins: physician-led AI that finally makes complex data as intuitive as a clinician's insight.[1][5]
Mendel.ai has raised $63.0M across 4 funding rounds. Most recently, it raised $40.0M Series B in March 2022.